Novigenix awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response 31 March 2025 Read More »
New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer 11 March 2025 Read More »
Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer 27 November 2024 Read More »
Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses 17 October 2024 Read More »
Prostate cancer breakthrough: Novigenix-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology 24 September 2024 Read More »
Novigenix unveils multimodal liquid biopsy approach at ESMO 2024, advancing precision medicine with AI-powered immune profiling 12 September 2024 Read More »
Novigenix honored as Best 2024 Technology Innovation in oncology by MATWIN Board 29 May 2024 Read More »
Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements 4 April 2024 Read More »
Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling 17 January 2024 Read More »
Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM 4 October 2023 Read More »
Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas 30 June 2023 Read More »
Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs 15 May 2023 Read More »
Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma 9 September 2022 Read More »
Novigenix and Philips Sign Technology License Agreement for Prostate Cancer Precision Oncology Products 9 March 2022 Read More »
Novigenix and Radboud University Medical Center Discover the First Blood-Based ImmunoTranscriptomic biomarkers for Response to Anti-PD-1 therapy 28 September 2021 Read More »
Novigenix Announces Election of Dr. Miro Venturi to its Board of Directors 31 August 2021 Read More »
